1. Academic Validation
  2. Stereoselective synthesis of a novel and bifunctional endothelin antagonist, IRL 3630

Stereoselective synthesis of a novel and bifunctional endothelin antagonist, IRL 3630

  • Bioorg Med Chem Lett. 1998 Aug 18;8(16):2247-52. doi: 10.1016/s0960-894x(98)00388-6.
J Sakaki 1 T Murata Y Yuumoto I Nakamura K Hayakawa
Affiliations

Affiliation

  • 1 Takarazuka Research Institute, Novartis Pharma K.K., Japan.
Abstract

IRL 3630 (3), a single enantiomer of IRL 3461 with more potency was identified. Coupling reaction of the racemic fragment (1) with the chiral (L)-valinesulfonamide (2) under a biphasic solvent system (CH2Cl2-H2O) successfully led to the predominant formation of the desired isomer (3) with concomitant isomerization of 1. IRL 3630, N-butanesulfonyl-[N-(3,5-dimethylbenzoyl)-N-methyl-3-[4-(5-+ ++isoxazolyl) -phenyl]-(D)-alanyl]-(L)-valineamide, is a highly potent and bifunctional (ETA + ETB) antagonist [Ki(ETA) = 1.5 nM, Ki(ETB) = 1.2 nM].

Figures
Products